Takeda to build new plant in Japan

Published: 17-Sep-2010
Manufacturing Finance

For production of oral, solid dosage formulations


Japanese drugmaker Takeda Pharmaceutical Company is to build a new JPY14bn (US$163m; €125m; £104m) manufacturing facility at its plant in Hikari City, Yamaguchi Prefecture in Japan.

Construction of the 13,000m2 facility will begin on 5 October, with completion expected by April 2012.

The company says the new flagship plant will operate 24/7 and conduct high-volume manufacturing of a wide range of oral, solid dosage formulations to treat diabetes and cardiovascular diseases.

  • Companies:
  • Takeda
See more

You may also like

Manufacturing

Takeda's NDA for metastatic colorectal cancer treatment

Read more
The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors

Trending Articles

  1. How AI can optimise your pharmaceutical manufacturing processes and raise throughput Artificial intelligence (AI) allows pharmaceutical manufacturers to perform predictive maintenance, which can reduce downtime and enhance process efficiency
  2. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
  3. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  4. Asymchem fully automates its therapeutic peptide manufacturing processes The company has facilitated the scale-up of its peptide manufacturing capabilities, with its production capacity now standing at 10,000 L
  5. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Manufacturing

Takeda's NDA for metastatic colorectal cancer treatment

The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors
Finance

Takeda Pharmaceutical to acquire GammaDelta Therapeutics

Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance

Takeda to evaluate Aptamer Group reagents for drug development

Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance

Adaptate Biotherapeutics raises $18 m in Series A2 funding

The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance

Novadiscovery enters clinical simulation collaboration with Takeda

This agreement builds on an existing relationship between the companies that began in 2017
Manufacturing

Future thoughts about pharmaceutical manufacturing

COPA-DATA's Giuseppe Menin and his colleagues from an ISPE working group discuss shifting from a systems to a service-oriented architecture
Manufacturing

Takeda opens cell therapy manufacturing facility in Boston

The next-generation cell therapies will initially focuse on oncology with potential to expand into other therapeutic areas
Subscribe now